These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39041683)

  • 1. TP53 and KMT2D mutations associated with worse prognosis in peripheral T-cell lymphomas.
    Wang L; Yang L; Guan F; Chen J; Cheng Y; Miao Y; He J; Cai Z; Huang H; Zhao Y
    Cancer Med; 2024 Jul; 13(14):e70027. PubMed ID: 39041683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.
    Laginestra MA; Cascione L; Motta G; Fuligni F; Agostinelli C; Rossi M; Sapienza MR; Righi S; Broccoli A; Indio V; Melle F; Tabanelli V; Calleri A; Novero D; Facchetti F; Inghirami G; Sabattini E; Bertoni F; Pileri SA
    Mod Pathol; 2020 Feb; 33(2):179-187. PubMed ID: 31028364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KMT2D and TP53 mutation status improve the prognostic value of the International Prognostic Index (IPI) stratification in ENKTL patients.
    Gao Y; Li Y; Ma G; Zhao G; Liu H
    Neoplasma; 2020 May; 67(3):636-643. PubMed ID: 32064880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathological features of angioimmunoblastic T-cell lymphomas with IDH2
    Steinhilber J; Mederake M; Bonzheim I; Serinsöz-Linke E; Müller I; Fallier-Becker P; Lemonnier F; Gaulard P; Fend F; Quintanilla-Martinez L
    Mod Pathol; 2019 Jul; 32(8):1123-1134. PubMed ID: 30952970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
    Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
    Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations in
    Gao LM; Zhao S; Zhang WY; Wang M; Li HF; Lizaso A; Liu WP
    Cancer Biol Ther; 2019; 20(10):1319-1327. PubMed ID: 31311407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characterization of follicular helper T-cell-derived peripheral T-cell lymphoma involving Waldeyer's ring.
    Wang J; Tang W; Zhang W; Wang J; Chen F; Zhong L; Chen Y; Chen G
    Virchows Arch; 2021 Aug; 479(2):355-363. PubMed ID: 33650043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
    Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
    Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
    Zhang P; Zhang M
    Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas.
    Ye Y; Ding N; Mi L; Shi Y; Liu W; Song Y; Shu S; Zhu J
    Exp Hematol Oncol; 2021 Feb; 10(1):9. PubMed ID: 33546774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
    Johnson WT; Ganesan N; Epstein-Peterson ZD; Moskowitz AJ; Stuver RN; Maccaro CR; Galasso N; Chang T; Khan N; Aypar U; Lewis NE; Zelenetz AD; Palomba ML; Matasar MJ; Noy A; Hamilton AM; Hamlin P; Caron PC; Straus DJ; Intlekofer AM; Lee Batlevi C; Kumar A; Owens CN; Sauter CS; Falchi L; Lue JK; Vardhana SA; Salles G; Dogan A; Schultz ND; Arcila ME; Horwitz SM
    Blood Adv; 2023 Sep; 7(17):5172-5186. PubMed ID: 37078708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients.
    de Pádua Covas Lage LA; Barreto GC; Culler HF; Cavalcante JB; de Oliveira Alves LB; Nardinelli L; Bendit I; Zerbini MCN; Rocha V; Pereira J
    Cancer Biomark; 2022; 35(2):179-191. PubMed ID: 36093687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.
    Vasmatzis G; Johnson SH; Knudson RA; Ketterling RP; Braggio E; Fonseca R; Viswanatha DS; Law ME; Kip NS; Ozsan N; Grebe SK; Frederick LA; Eckloff BW; Thompson EA; Kadin ME; Milosevic D; Porcher JC; Asmann YW; Smith DI; Kovtun IV; Ansell SM; Dogan A; Feldman AL
    Blood; 2012 Sep; 120(11):2280-9. PubMed ID: 22855598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression.
    Huang HS; Liao CK; Liu TT; You HL; Wang MC; Huang WT
    Hum Pathol; 2018 Oct; 80():145-151. PubMed ID: 29885407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of
    Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
    J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Ferrero S; Rossi D; Rinaldi A; Bruscaggin A; Spina V; Eskelund CW; Evangelista A; Moia R; Kwee I; Dahl C; Di Rocco A; Stefoni V; Diop F; Favini C; Ghione P; Mahmoud AM; Schipani M; Kolstad A; Barbero D; Novero D; Paulli M; Zamò A; Jerkeman M; da Silva MG; Santoro A; Molinari A; Ferreri A; Grønbæk K; Piccin A; Cortelazzo S; Bertoni F; Ladetto M; Gaidano G
    Haematologica; 2020 Jun; 105(6):1604-1612. PubMed ID: 31537689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
    Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.